Put Options

8 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$5.98 - $11.18 $9,568 - $17,888
-1,600 Reduced 12.5%
11,200 $125,000
Q1 2024

May 15, 2024

BUY
$4.4 - $6.74 $38,720 - $59,312
8,800 Added 220.0%
12,800 $84,000
Q4 2023

Feb 14, 2024

SELL
$3.08 - $4.52 $17,556 - $25,763
-5,700 Reduced 58.76%
4,000 $18,000
Q3 2023

Nov 14, 2023

SELL
$3.47 - $4.61 $200,566 - $266,458
-57,800 Reduced 85.63%
9,700 $34,000
Q2 2023

Aug 14, 2023

SELL
$3.12 - $4.22 $40,872 - $55,282
-13,100 Reduced 16.25%
67,500 $249,000
Q1 2023

May 15, 2023

BUY
$3.01 - $3.87 $13,544 - $17,415
4,500 Added 5.91%
80,600 $266,000
Q4 2022

Feb 14, 2023

BUY
$2.47 - $3.88 $15,067 - $23,668
6,100 Added 8.71%
76,100 $295,000
Q3 2022

Nov 14, 2022

SELL
$2.03 - $2.86 $8,526 - $12,012
-4,200 Reduced 5.66%
70,000 $170,000

Others Institutions Holding ADMA

About ADMA BIOLOGICS, INC.


  • Ticker ADMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 196,356,992
  • Market Cap $3.29B
  • Description
  • ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...
More about ADMA
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.